Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
Robert Zeiser, MD, professor of hematology and oncology at the University Medical Center Freiburg, discusses the findings from the phase 3 REACH3 clinical trial (NCT03112603) of ruxolitinib (Jakafi) as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
The study demonstrated that treatment with ruxolitinib induced a greater objective response rate (ORR) compared with best available therapy, which was evaluated as the control. At week 24, the ORR with ruxolitinib was 49.7%, and the ORR in the BAT arm was 25.6%, says Zeiser.
Treatment also appeared tolerable, with similar tolerability observed in both groups on the study. No new safety signs were observed, and adverse events associated with treatment were consistent with the known toxicity profile, says Zeiser. The most common toxicities in the ruxolitinib arm compared with the control were anemia (29% vs 12%), hypertension (15% vs 12%), and pyrexia (15% vs 9%).
Zeiser presented these findings from the REACH3 study during the 2020 ASH Annual Meeting.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More